JP2015509950A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509950A5 JP2015509950A5 JP2014559248A JP2014559248A JP2015509950A5 JP 2015509950 A5 JP2015509950 A5 JP 2015509950A5 JP 2014559248 A JP2014559248 A JP 2014559248A JP 2014559248 A JP2014559248 A JP 2014559248A JP 2015509950 A5 JP2015509950 A5 JP 2015509950A5
- Authority
- JP
- Japan
- Prior art keywords
- oligopeptide
- acylated peptide
- terminal acylated
- peptide
- terminal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 15
- 108010038807 Oligopeptides Proteins 0.000 claims 14
- 102000015636 Oligopeptides Human genes 0.000 claims 14
- 150000001413 amino acids Chemical class 0.000 claims 3
- -1 aromatic amino acid Chemical class 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 150000004665 fatty acids Chemical group 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 2
- 102000004400 Aminopeptidases Human genes 0.000 claims 1
- 108090000915 Aminopeptidases Proteins 0.000 claims 1
- 102000005367 Carboxypeptidases Human genes 0.000 claims 1
- 108010006303 Carboxypeptidases Proteins 0.000 claims 1
- 108090000317 Chymotrypsin Proteins 0.000 claims 1
- 108010067372 Pancreatic elastase Proteins 0.000 claims 1
- 102000016387 Pancreatic elastase Human genes 0.000 claims 1
- 108090000631 Trypsin Proteins 0.000 claims 1
- 102000004142 Trypsin Human genes 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 229960002376 chymotrypsin Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000017854 proteolysis Effects 0.000 claims 1
- 230000002797 proteolythic effect Effects 0.000 claims 1
- 239000012588 trypsin Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12157616 | 2012-03-01 | ||
| EP12157616.9 | 2012-03-01 | ||
| US201261625896P | 2012-04-18 | 2012-04-18 | |
| US61/625,896 | 2012-04-18 | ||
| PCT/EP2013/054177 WO2013128003A1 (en) | 2012-03-01 | 2013-03-01 | N-terminally modified oligopeptides and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015509950A JP2015509950A (ja) | 2015-04-02 |
| JP2015509950A5 true JP2015509950A5 (enExample) | 2016-04-21 |
| JP6382111B2 JP6382111B2 (ja) | 2018-08-29 |
Family
ID=49081680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014559248A Expired - Fee Related JP6382111B2 (ja) | 2012-03-01 | 2013-03-01 | Ｎ末端改変オリゴペプチド及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20150038435A1 (enExample) |
| EP (1) | EP2820150A1 (enExample) |
| JP (1) | JP6382111B2 (enExample) |
| CN (1) | CN104136626B (enExample) |
| WO (1) | WO2013128003A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY36870A (es) * | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
| AU2017273857B2 (en) | 2016-06-01 | 2021-08-19 | Athira Pharma, Inc. | Compounds |
| AU2017332408B2 (en) | 2016-09-23 | 2022-02-10 | Hanmi Pharm. Co., Ltd. | Insulin analogs with reduced affinity to insulin receptor and use thereof |
| RU2019125634A (ru) * | 2017-02-06 | 2021-03-09 | Элайз Фарма Сас | Соединения, композиции и их применения для улучшения костных расстройств |
| AU2018239037B2 (en) | 2017-03-23 | 2022-05-26 | Hanmi Pharm. Co., Ltd. | Insulin analog complex with reduced affinity for insulin receptor and use thereof |
| EP3728304B1 (en) | 2017-12-21 | 2025-02-12 | Bachem Holding AG | Solid phase synthesis of acylated peptides |
| US20210045419A1 (en) * | 2018-02-20 | 2021-02-18 | University Of Manitoba | Food Protein-Derived Peptides as Bitter Taste Blockers |
| WO2019224786A1 (en) * | 2018-05-24 | 2019-11-28 | Alize Pharma Iii Sas | Heparin-binding domain of igfbp-2 in the treatment of metabolic disorders |
| KR102282558B1 (ko) * | 2018-07-06 | 2021-07-28 | 애니젠 주식회사 | 펩타이드 복합체를 유효성분으로 함유하는 미세먼지 제거 또는 흡착용 화장료 조성물 |
| KR102507392B1 (ko) * | 2020-06-18 | 2023-03-08 | 애니젠 주식회사 | 유기산-올리고펩타이드 복합체를 유효성분으로 포함하는 피부 노화 및 주름 개선용 조성물 |
| CA3194956A1 (en) | 2020-09-11 | 2022-03-17 | Glympse Bio, Inc. | Ex vivo protease activity detection for disease detection/diagnostic, staging, monitoring and treatment |
| CA3204051A1 (en) | 2021-01-20 | 2022-07-28 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| WO2023044290A1 (en) | 2021-09-15 | 2023-03-23 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
| US20250223627A1 (en) * | 2022-03-09 | 2025-07-10 | Glympse Bio, Inc. | Fluorogenic substrates for aminopeptidase detection in biofluids |
| EP4504711A2 (en) * | 2022-04-08 | 2025-02-12 | Sunvax MRNA Therapeutics Inc. | Ionizable lipid compounds and lipid nanoparticle compositions |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05213990A (ja) * | 1991-02-27 | 1993-08-24 | Taisho Pharmaceut Co Ltd | トリペプチド誘導体 |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| GB9409496D0 (en) * | 1994-05-12 | 1994-06-29 | London Health Ass | Method for improving glycaemic control in diabetes |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| EP1115847A1 (en) * | 1998-09-25 | 2001-07-18 | Children's Medical Center Corporation | Short peptides which selectively modulate the activity of protein kinases |
| FR2864085B1 (fr) * | 2003-12-18 | 2010-09-17 | Centre Nat Rech Scient | Nouveaux modulateurs du proteasome |
| US20070292354A1 (en) * | 2004-09-23 | 2007-12-20 | Guerbet | Contrast Agents Encapsulating Systems for Cest Imaging |
| CA2597191C (en) * | 2005-02-09 | 2014-04-01 | Helix Biomedix Inc. | Antimicrobial hexapeptides |
| DE102006047529A1 (de) * | 2006-10-07 | 2008-04-10 | Evonik Goldschmidt Gmbh | Oligopeptide enthaltende dermatologische Zusammensetzungen zur Steigerung der Hautempfindlichkeit und der neuronalen Reizwahrnehmung |
| CA2989778C (en) * | 2007-01-19 | 2020-06-30 | Kai Pharmaceuticals, Inc. | Method of modifying peptide compositions |
| WO2008128038A2 (en) * | 2007-04-13 | 2008-10-23 | The Scripps Research Institute | Methods and compositions for treating cardiac dysfunctions |
| EP2514406A1 (en) | 2007-06-01 | 2012-10-24 | Novo Nordisk A/S | Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier |
| WO2009030738A1 (en) | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| ES2342754B1 (es) * | 2008-10-03 | 2011-05-11 | Lipotec, S.A. | Peptidos utiles en el tratamiento y/o cuidado de la piel, mucosas, cuero cabelludo y/o cabello y su uso en composiciones cosmeticas o farmaceuticas. |
| EP2370059A1 (en) | 2008-11-28 | 2011-10-05 | Novo Nordisk A/S | Pharmaceutical compositions suitable for oral administration of derivatized insulin peptides |
| CA2786953A1 (en) * | 2010-01-12 | 2011-07-21 | Florian Anders Foeger | Pharmaceutical compositions for oral administration of insulin peptides |
| EP2610243A4 (en) * | 2010-08-23 | 2014-04-02 | Postech Acad Ind Found | Labeling agent and amino acid sequence using same, and method for performing simultaneous quantitative analysis of multiple proteins |
| CN102219850A (zh) * | 2011-05-03 | 2011-10-19 | 上海格尼生物技术有限公司 | 新的长效glp-1化合物 |
| CN102311483A (zh) * | 2011-07-13 | 2012-01-11 | 大连伊美生物科技有限公司 | 一种低溶血性抗菌脂肽及其制备方法 |
-
2013
- 2013-03-01 CN CN201380011936.8A patent/CN104136626B/zh not_active Expired - Fee Related
- 2013-03-01 US US14/380,914 patent/US20150038435A1/en not_active Abandoned
- 2013-03-01 JP JP2014559248A patent/JP6382111B2/ja not_active Expired - Fee Related
- 2013-03-01 WO PCT/EP2013/054177 patent/WO2013128003A1/en not_active Ceased
- 2013-03-01 EP EP13707004.1A patent/EP2820150A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015509950A5 (enExample) | ||
| Kimura et al. | KMI-358 and KMI-370, highly potent and small-sized BACE1 inhibitors containing phenylnorstatine | |
| JP2019533722A5 (enExample) | ||
| ES2449615T3 (es) | Péptidos y su uso | |
| NO20071369L (no) | Antimikrobiske peptider omfattende et arginin- og/eller lysin-inneholdende motiv | |
| EP2390265A3 (en) | Insulinotropic peptide derivative wherein its N-terminal amino acid is modified | |
| HRP20140616T1 (hr) | Peptidni analog oksintomodulina | |
| HRP20201081T1 (hr) | Inhibitorni peptidi porijeklom od trem-sličnog transkripta 1 (tlt-1) i njihove uporabe | |
| JP5819889B2 (ja) | 炎症性メディエーターの放出を減弱させるための方法及びそれにおいて有用なペプチド | |
| CN103476792B (zh) | 人乳铁蛋白衍生肽及其用途 | |
| JP2012506442A5 (enExample) | ||
| HRP20171048T1 (hr) | Novi agonisti angiotenzinskog receptora tipa 2 (at2) i njihove upotrebe | |
| JP2010512326A5 (enExample) | ||
| WO2007061829A3 (en) | Pharmaceutical composition | |
| WO2008047370A3 (en) | Compositions and methods for inducing angiogenesis | |
| WO2008096816A1 (ja) | 血管新生誘導剤及びそれに用いられるポリペプチド | |
| WO2012104462A1 (es) | Heptapéptidos y su uso para el control de la hipertensión | |
| AU2003264679A8 (en) | Peptides having antimicrobial properties and compositions containing same in particular for preserving foods | |
| Rall et al. | Boswellic acids and protease activities | |
| BR112012012190A2 (pt) | peptídeo, método e kit de diagnóstico e composição farmacêutica | |
| JP2015533821A5 (enExample) | ||
| JP2013529600A5 (enExample) | ||
| Bose et al. | Camostat in COVID-19 | |
| ES2321358B1 (es) | Uso de peptidos derivados de la lactoferrina para preparar formulaciones inhibidoras de la enzima conversora de angiotensina i. | |
| ES2320057B1 (es) | Uso de exapeptidos para preparar formulaciones inhibidoras de la enzima conversora de angiotensina i. |